News | April 03, 2012

PCI-Associated Renal Complications Increase Significantly Among Medicare Patients

Study warrants focus on contrast-induced nephropathy

April 3, 2012 — Incidences of renal complications, specifically acute renal failure (ARF) and new hemodialysis (HD), continue to increase significantly among Medicare beneficiaries (MB) admitted for percutaneous coronary intervention (PCI). This was according to a study presented last week at the American College of Cardiology’s (ACC) 61st Annual Scientific Session.

While patients admitted with impaired renal function are at increased risk, approximately 10 percent of elective patients will suffer renal complications without prior indicators. Researchers said the findings warrant more focus on implementation of a contrast-induced nephropathy (CIN) protocol to reduce complications.

The study, conducted Oct. 1, 2008 to Sept. 30, 2010, was designed to report two-year trends in PCI-associated renal failure. The study group included all Medicare patients admitted for a PCI without CABG (coronary artery bypass graft) surgery or valve surgery in an acute care hospital. The study population was divided into two sub-samples:

  • Elective PCI: Patients who did not have primary ST segment elevation myocardial infarction (STEMI) and did not arrive in cardiogenic shock or cardiac arrest.
  • Non-Elective PCI: All MBs not undergoing an elective PCI.

 

All patients studied experienced significant increases in both acute renal failure (ARF) and new hemodialysis (HD) year over year, by 29 percent and 21 percent, respectively. The percentage increase for both complications was slightly higher for those patients undergoing elective PCI, while the increase in ARF among patients undergoing non-elective PCI was nearly double that of elective patients.

“The rise in renal complications is concerning, given their close association with worse morbidity and mortality,” said April Simon, R.N., MSN, one of the researchers and president of Cardiac Data Solutions, which conduced the study. “This data suggests that increased focus on contrast-induced nephropathy prevention protocols may improve clinical outcomes. Any patient receiving contrast is at risk for CIN; insuring that the amount of contrast is minimized and paying particular attention to hydration are imperative.”

For more information: www.ereleases.com/pic/Cardiac-Data-Solutions.pdf.

Related Content

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | September 12, 2018
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore co
Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents
News | Contrast Media | January 19, 2018
Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced renal toxicity....
FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents. Image by Marilyn Fornell
News | Contrast Media | September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media | August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and...
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
Bayer Arterion contrast Injector used to administer medical imaging contrast for CT scans.

Bayer Healthcare's Arterion contrast injector system.

Feature | Contrast Media | June 19, 2017 | Dave Fornell
Here are several updates in medical imaging...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication
Technology | Contrast Media | February 02, 2017
Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity...
CT, computed tomography, IV contrast media, acute kidney injury risk, Annals of Emergency Medicine study

A new study in Annals of Emergency Medicine finds no association between intravenous contrast media used in computed tomography (CT) and kidney damage. Roughly 80 million doses of IV contrast media are given every year. Credit: American College of Emergency Physicians

News | Contrast Media | January 30, 2017
Intravenous contrast media (typically iohexol or iodixanol) used in computed tomography (CT) does not appear to be...
Overlay Init